Morgan Stanley Maintains Underweight on Macerich, Lowers Price Target to $8.5

Morgan Stanley analyst Richard Hill maintains Macerich (NYSE:MAC) with a Underweight and lowers the price target from $11.25 to $8.5.

Morgan Stanley analyst Richard Hill maintains Macerich (NYSE:MAC) with a Underweight and lowers the price target from $11.25 to $8.5.

Total
0
Shares
Related Posts
Read More

Detailed Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study In Autosomal Dominant Alzheimer’s Disease Presented At AAIC; Says Crenezumab Was Safe And Well Tolerated With No Cases Of ARIA-E Observed During The Up To Eight-Year Study

Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year study As previously reported, numerical differences favoring crenezumab over placebo were confirmed across the

ACIU